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Ovarian cancer is the most common cause of death among patients
with gynaecological malignancies (Parker et al, 1997). At the time
of presentation the majority of patients have advanced disease,
which is not amenable to cure by surgery alone. The standard
treatment is a multimodality approach, consisting of cytoreductive
surgery and platinum/paclitaxel combination chemotherapy
(McGuire and Ozols, 1998). Salvage chemotherapy may result in
prolonged secondary remissions with alleviation of symptoms and
improvement of the quality of life. The response to salvage
chemotherapy is related to the therapy-free interval. The longer
this interval, the greater the probability of response to retreatment
with platinum-based regimens. Dose-intense combination therapy
might increase the response rates and the disease and overall
survival. There is no standard therapy for patients with early recur-
rent ovarian cancer. Studies with new agents, including topotecan,
have shown activity (Creemers et al, 1994; Swisher et al, 1997; ten
Bokkel Huinink et al, 1997). Cisplatin administered weekly at a
dose of 70 mg m–2 in combination with either continuous oral
etoposide or with weekly i.v. paclitaxel to patients with progres-
sive or recurrent ovarian cancer yielded a high dose intensity with
response rates up to 84% in second-line treatment (van der Burg
et al, 1996, 1998). 
Since there is preclinical evidence of synergistic action between
cisplatin and topotecan (Chou et al, 1994; Romanelli et al, 1998)
and both agents are active in ovarian cancer, while their toxicity
profile is mostly non-overlapping, we investigated a dose-intense
weekly combination of these agents in recurrent ovarian cancer.
We administered topotecan orally since preclinical studies
suggested that prolonged exposure, as can be achieved more
conveniently by oral administration, might result in higher antitu-
mour activity (Hochster et al, 1994). 
Combining topotecan with i.v. cisplatin in more conventional 
3-weekly schedules required considerable dose reduction of
topotecan as compared to the single agent dose, even with G-CSF
support (Miller et al, 1994). Dose-limiting toxicities (DLT)
consisted mainly of haematological toxicity, which was sequence
dependent, with topotecan following cisplatin as the most haema-
totoxic sequence (Rowinsky et al, 1996; de Jonge et al, 2000).
Whether drug sequencing clinically is also relevant for antitumour
activity is as yet unknown. To evaluate the sequence-dependent
effects we administered the oral topotecan 2 days a week
preceding weekly cisplatin or following cisplatin. 
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Summary Both weekly cisplatin chemotherapy and single agent topotecan have proven to be effective in recurrent ovarian cancer. Preclinical
data show synergism between cisplatin and topotecan. Side effects for this combination are drug sequence dependent and predominantly
haematologic. Since preclinical data suggest that Cremophor EL (CrEL), the formulation vehicle of paclitaxel, has a protective effect on
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topotecan administered on day 1, 2, 8, 9, 15, 16, 29, 30, 36, 37, 43, 44 were combined with weekly cisplatin 70 mg m–2 d–1 on day 1, 8, 15, 29,
36, 43 (scheme A) or with the presumably less myelotoxic sequence weekly cisplatin day 2, 9, 16, 30, 37, 44 (scheme B). In scheme C, CrEL
12 ml was administered prior to cisplatin in the sequence of Scheme A. 18 patients have received a total of 85 courses. In scheme A 4/10
patients, all treated with topotecan 0.45 mg m–2 d–1, experienced DLT: 1 patient had vomiting grade 4, 1 patient had grade 4 neutropenia >5
days, 1 patient had >2 weeks delay due to thrombocytopenia and 1 patient due to neutropenia. Both patients in scheme B (topotecan 0.45 mg
m–2 d–1) had DLT due to a delay > 2 weeks because of prolonged haematological toxicity. No DLT was observed in the first 3 patients in
scheme C (topotecan 0.45 mg m–2 d–1). However, 2 out of 3 patients treated at dose level topotecan 0.60 mg m–2 d–1 in scheme C experienced
DLT due to >2 weeks delay because of persistent thrombocytopenia or neutropenia. We conclude that there is a modest clinical effect of CrEL
on haematological toxicity for this cisplatin-based combination regimen, which seems to reduce these side effects but does not really enable
an increase of the oral topotecan dose. © 2001 Cancer Research Campaign http://www.bjcancer.com
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The third schedule was based on the preclinical observation that
CrEL protected from cisplatin-induced haematological toxicity
(Ma et al, 1996; de Vos et al, 1997; Badary et al, 2000). In these
studies CrEL inhibited DNA adduct formation and the intracel-
lular accumulation of cisplatin in human leukocytes, and in mice
CrEL protected from cisplatin induced myelotoxicity. We might
have observed this effect clinically in a study with weekly cisplatin
preceded by paclitaxel (van der Burg et al, 1998). In this study an
unexpected high dose of weekly paclitaxel 90 mg m–2 could be
safely combined with weekly cisplatin 70 mg m–2. Therefore, to
evaluate the possibility of an increase of the oral topotecan dose
i.v. CrEL was administered prior to the weekly cisplatin infusions
in the third cohort of the current study. 
PATIENTS AND METHODS 
Patients selection 
Patients with progressive or recurrent ovarian cancer were eligible
for this phase I study. In case of prior treatment with a weekly
cisplatin-based regimen, a minimal progression-free interval of 3
months after the completion of the weekly cisplatin schedule, was
mandatory. Other eligibility criteria included: WHO performance
status 0–2, evaluable disease, no more than 2 prior chemotherapy
regimens, no chemotherapy, hormonal or radiotherapy for at least
4 weeks prior to entry in the study, no signs of bowel obstruction,
neutrophils ≥ 1.5 × 109 l–1, platelet count ≥ 100 × 109 l–1, total
bilirubin < 1.25 times the upper limit of normal, creatinine clear-
ance > 60 ml min–1, peripheral neurotoxicity ≤ grade 1, no condi-
tion precluding adequate intake of oral topotecan, and no prior
therapy with a topoisomerase I inhibitor. The study was approved
by the institution’s medical ethics committee and all patients
signed written informed consent prior to entry in the study. 
Treatment assessment 
Before therapy a complete medical history was taken and a phys-
ical examination was performed. A complete blood count (CBC)
including white blood cell (WBC) differential, and serum
biochemistry, which involved sodium, potassium, calcium, phos-
phorus, urea, creatinine, total protein, albumin, total bilirubin,
alkaline phosphatase, aspartate aminotransferase (ASAT), alanine
transferase (ALAT), γ -glutamyl transferase, glucose and uric acid,
were performed, as was 24-hour creatinine clearance. During the
induction regimen, weekly evaluations included history, physical
examination, toxicity assessment according to the National Cancer
Institute Common Toxicity Criteria (NCI-CTC) version 2.0, and
serum chemistry. CBC was determined twice weekly. Tumour
evaluation according to the World Health Organisation (WHO)
criteria for response was performed before and after the induction
regimen and every 2 courses during the maintenance regimen. 
Drug administration 
Cisplatin (Platosin) was supplied as a powder by Pharmachemie
(Haarlem, the Netherlands). All patients received cisplatin
dissolved in 250 ml of hypertonic saline (3% (w/v) sodium chlo-
ride) as a 3-h infusion on a weekly base during the induction
regimen and 3-weekly during the maintenance regimen. Topotecan
capsules containing either 0.25 or 1.00 mg of the active compound
were supplied by Smith Kline Beecham Pharmaceuticals (Harlow,
UK). Topotecan was administered orally immediately at the start
of the cisplatin infusion and the following day (scheme A and C)
or the previous day (scheme B) during the induction regimen and
for 5 consecutive days during the maintenance regimen (days 1–5)
on an empty stomach, at least 10 min before meals. CrEL was
obtained from Duchefa (Haarlem, the Netherlands), and adminis-
tered through a polyvinylchloride-free infusion system in 3 h
before the cisplatin infusions in scheme C. 
In all patients standard pre-medication consisted of ondansetron
(8 mg i.v.) combined with dexamethasone (10 mg i.v.), and an
additional 2 mg of clemastine in scheme C. To avoid cisplatin-
induced renal damage, the administration of cisplatin was
preceded by the infusion of 1 l of a mixture of 2.5% (w/v) dextrose
and 0.45% (w/v) sodium chloride over 4 h, and followed by
another 3 l with the addition of 20 mM potassium chloride and 2 g l–1
magnesium sulfate applied over 16 h. Further anti-emetic therapy
consisted of oral dexamethason 3 mg twice daily and ondansetron
8 mg twice daily on the first 2 days following cisplatin infusion,
followed by oral metoclopramide or domperidon as needed. 
Treatment and dose escalation 
Patients were treated with an induction regimen consisting of oral
topotecan day 1, 2, 8, 9, 15, 16, 29, 30, 36, 37, 43, 44 in combina-
tion with weekly cisplatin 70 mg m–2 d–1 on day 1, 8, 15, 29, 36, 43
(scheme A) or the same administration scheme of topotecan in the
presumably less myelotoxic sequence with weekly cisplatin on
day 2, 9, 16, 30, 37, 44 (scheme B). In scheme C CrEL (12 ml) was
administered prior to cisplatin using the sequence of scheme A. The
dose of CrEL was similar to that administered with paclitaxel at a
dose of 90 mg m–2, as used in our weekly cisplatin/paclitaxel
schedule.8 All schemes are outlined in Figure 1. The topotecan
starting dose was 0.45 mg m–2 d–1, a dose deduced from previous
phase I studies with single agent topotecan, and our recently
completed study with oral topotecan given daily 5 times every 3
weeks in combination with 3-weekly cisplatin (de Jonge et al,
2000). Topotecan dose was escalated depending on the observed
toxicity. Weekly treatment was postponed if the neutrophil count
had not recovered to ≥ 1.0 × 109 l–1 and the platelet count to ≥ 100 ×
109 l–1 on the day of retreatment. If the treatment was delayed,
haematology was assessed twice a week to enable treatment re-start




d1d2 d8 d9 d15 d29 d30 d36 d37 d43 d44 d16
d1d2 d8 d9 d15 d29 d30 d36 d37 d43 d44 d16
d1d2 d8 d9 d15 d29 d30 d36 d37 d43 d44 d16
Figure 1 Outline of the different induction regimens: scheme A, B and C.
Cisplatin administration (closed symbols), oral topotecan administration
(open symbols) and CrEL administration (grey symbols)  1126 H Gelderblom et al
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NCI-CTC version 2.0 grade 4 neutropenia lasting for 5 days or
more, or complicated with fever requiring hospitalisation, grade 4
thrombocytopenia and/or non-haematological toxicity ≥ grade 3,
excluding nausea. Treatment delay of more than 2 weeks due to
toxicity was also considered DLT. Dose (de-)escalation, if any,
was based on the toxicities observed at previous dose levels. In all
patients response evaluation took place after completion of the
induction regimen. In case of response or stable disease it was left
to the judgement of the treating physician to proceed with a main-
tenance therapy consisting of cisplatin and/or oral topotecan in a
3-weekly schedule. 
Dose modifications 
If neutrophils were < 1.0 × 109 l–1and/or platelet count ≤ 100 × 109 l–1
on day 8, 15, 29, 36, 43 or preceding each maintenance course, treat-
ment was delayed until recovery. 
Prior to the first course creatinine clearance should exceed
60 ml min–1, as stated in the inclusion criteria. If the creatinine
clearance was impaired due to dehydration or insufficient intake of
fluids, prehydration was intensified followed by new creatinine
clearance measurements. If the creatinine clearance after addi-
tional prehydration remained < 50 ml min–1 during the induction
regimen, cisplatin was withdrawn from the combination regimen. 
Sample collection and drug analysis 
Blood samples for pharmacokinetics of cisplatin and topotecan
were obtained on the day of cisplatin infusion during the first 3
weekly administrations of the induction regimen in scheme C. All
blood samples were obtained and analysed as described previously
(de Jonge et al, 2000). 
RESULTS 
18 patients entered this study between March 1999 and May 2000.
Patient characteristics are listed in Table 1. All patients had
progressive or recurrent ovarian cancer after prior cisplatin-based
chemotherapy and were eligible. The median WHO performance
status was 1 (range 0–2), and age 51 years (range 34–68). The
median cisplatin-free interval of 7 months (range 0–17) was short,
rendering a poor prognosis. A total of 85 weekly induction admin-
istrations (cycles) were given. Overall, only 7 patients received all
6 weekly induction administrations: 2 patients were withdrawn
because of an allergic reaction to cisplatin infusion during the 4th
administration, 7 patients could not complete all 6 induction
administrations due to haematological toxicity, 1 patient was not
able to receive her 6th induction administration due to electrolyte
disturbances related to the weekly platinum infusions, and 1
patient went off study after the 4th cycle due to early progressive
disease. 
In scheme A, 10 patients received cisplatin 70 mg m– 2 d–1 on
day 1 followed by oral topotecan at 0.45 mg m–2 d–1 on day 1 and
2. In scheme B, a total of 2 patients were treated at the same dose
level in the reverse sequence. In scheme C, 3 patients were treated
at the initial dose level of topotecan at 0.45 mg m–2 d–1 on day 1
and 2 and another 3 patients at 0.6 mg m–2 d–1, all preceded by
CrEL and cisplatin on day 1. 
Haematological toxicity and in one case vomiting were the
dose-limiting toxicities (DLTs) of the induction regimen. In
scheme A 4 out of 10 patients experienced DLT, in scheme B 2 out
of 2 and in scheme C no DLTs were observed at the initial dose
level and in 2 out of 3 at the higher dose level. The toxicity of the
induction regimen A, B and C will be described separately in more
detail in the following paragraphs. The main toxicity of the main-
tenance regimen was uncomplicated myelotoxicity. 
Haematological toxicity 
The haematological toxicity observed during the induction
regimen is shown in Table 2. In scheme A, 3 patients were judged
as having DLT for haematological reasons: 1 patient had her 3rd
weekly cisplatin administration (cycle) postponed more than 2
weeks due to persistent thrombocytopenia, 1 patient developed
grade 4 neutropenia lasting for 5 days or more after cycle 3 and 1
patient had grade 4 thrombocytopenia, following cycle 3. In
scheme B both patients had DLT based on delay of their 4th cycle
by more than 2 weeks because of prolonged neutropenia (1
patient) or neutro-and thrombocytopenia (1 patient). Both patients
continued induction treatment with weekly cisplatin monotherapy.
At the first dose level in scheme C, with the addition of CrEL, no
Table 1 Patient characteristics 
Characteristic No. of patients 
No. of patients entered 18 
No. of patients assessable 18 
Cisplatin free interval, months 
<6 7  
6–12 8 








Table 2 Haematological toxicity (worst per cycle) 
Scheme Topotecan mg m–2 day–1 No. of patients/cycles Leukocytopenia Neutropenia Thrombocytopenia 
34 3 4 34  
A 0.45 10/43 2 1 5 4 3 1 
B 0.45 2/6 1 0 1 1 0 1 
C 0.45 3/18 0 0 1 1 0 0 
Ca 0.60 3/18 1 0 1 1 2 0 
aPatients who had their topotecan dose reduced to 0.45 mg m–2 d–1 due to earlier toxicity were included in this table. Oral topotecan and weekly cisplatin 1127
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DLTs were observed, rendering this dose level feasible. Only 1
grade 4 neutropenia was observed and all patients completed the
weekly cisplatin on time. However, in scheme C, at the dose of
topotecan at 0.6 mg m–2 d–1, again DLT was encountered in 2 out
of 3 patients. The 3rd cycle was delayed by more than 2 weeks
because of thrombocytopenia in 1 patient and thrombocytopenia
followed by neutropenia in another patient. The MTD in scheme C
was determined as topotecan at 0.45 mg m– 2d–1 (days 1 and 2)
combined with CrEL 12 ml and cisplatin at 70 mg m–2 week–1. 
In scheme A, B, C first dose level and C highest dose level, the
percentage of cycles associated with grade 3 or 4 neutropenia were
respectively: 21, 33, 11 and 11%, but none of the neutropenic
periods was complicated by fever. Thrombocytopenia grade 3 or 4
was observed in only a limited number of cycles (9, 17, 0 and 6%),
all without bleeding, only 2 patients received a prophylactic
platelet transfusion. Mild (grade 1 or 2) anaemia occurred in
almost all patients, only 3 patients (1 in scheme A and 2 in scheme
C) had grade 3 anaemia. A total of 20 blood transfusions were
administered during induction chemotherapy (8 in scheme A, 4 in
scheme B and 8 in scheme C). 3 patients received erythropoietine
injections during the last induction cycles. 
Non-haematological toxicity 
Nausea and vomiting were the most frequently reported non-
haematological side effects (data shown in Table 3). One patient in
scheme A was judged as having DLT because of grade 4 vomiting
1 week after cycle 6. The event was only possibly related to the
chemotherapy, because she had experienced these symptoms once
prior to treatment. 
Other side effects included fatigue (grade 1 in 28%, grade 2 in
11%), alopecia in 22%, tinnitus in 17% and nephrotoxicity grade 1
in 28%. Mild headache was reported in 50% of patients, but this
might also partially be related to the administration of
ondansetron. 
2 patients were withdrawn from the study because of an allergic
reaction to cisplatin. These patients continued treatment with oral
topotecan monotherapy. 
Antitumour activity 
3 patients were not assessable for response due to early discontin-
uation of the induction regimen for reasons other than progression
of the disease. 7 patients had early response evaluation after
having received more than 3 weekly cycles. Of the 15 patients
evaluable for response after the weekly induction regimen, 9
patients (60%) reached a partial response, another 5 (33%) had
stable disease, only 1 patient (7%) had early progressive disease.
Due to the various maintenance treatments and the small sample
size, assessment of the overall response and response duration is
not really possible. 
Pharmacokinetics 
Full kinetic data following the administration of cisplatin and
topotecan during the first 3 cycles were obtained from 6 patients in
scheme C. Cisplatin and topotecan pharmacokinetic data (apparent
clearance of unbound platinum fraction of 32.2 ± 24.8 l h–1 m–2
(mean ± SD), cisplatin unbound/bound ratio of 0.082 ± 0.045,
apparent oral topotecan clearance of 142 ± 95.7 l h–1 m–2 and
topotecan lactone to total drug AUC ratio of 0.36 ± 0.05) were
comparable to single agent data (Gerrits et al, 1998). The vari-
ability in Cmax and AUC for the 6 patients who had full kinetic data
were 4.97–41.8% and 28.7–32.2%, respectively, which is also in
agreement with earlier data (Gerrits et al, 1998; Gelderblom et al,
2000a). These findings indicate that there was no cisplatin/-
topotecan/CrEL pharmacokinetic drug interaction. 
DISCUSSION 
This study, using weekly cisplatin, with and without CrEL, in
combination with oral topotecan in different sequences, was based
on a number of (pre-)clinical observations: (a) combining cisplatin
and topotecan, 2 potentially active agents in ovarian cancer in a
dose-dense scheme, is attractive given their preclinical synergism;
(b) Dose-dense weekly cisplatin combination chemotherapy regi-
mens seem to yield improved response rates in recurrent ovarian
cancer; (c) Administration of oral topotecan enables prolonged
systemic exposure, which is more effective in pre-clinical models
and (d) single agent oral topotecan is as effective as i.v., with less
grade 4 neutropenia in advanced ovarian cancer (Gore et al, 1998),
(e) while patients have a preference for oral chemotherapy when
equally effective (Liu et al, 1997). In order to study drug-sequence-
dependent haematological effects for the combination cisplatin
and i.v. topotecan, with cisplatin following topotecan as the least
toxic sequence, both administration sequences were evaluated.
Since, in the 3-weekly schedules combining cisplatin and topotecan,
considerable dose reduction of topotecan was necessary, compared
with single agent dose, we also studied the possible myeloprotective
effect of co-administration of CrEL in scheme C. CrEL was used
since in vitro studies indicate that CrEL selectively inhibits cisplatin
accumulation in white blood cells, but not in tumour cells (Ma et al,
1996; de Vos et al, 1997). This effect might have been responsible
for improvement of therapeutic index observed in a combination
study with paclitaxel (van der Burg et al, 1998). 
In the current study, in this quite heavily pretreated population,
haematological toxicity was the main dose-limiting side effect.
However with no patients experiencing febrile neutropenia or
Table 3 Non-haematological toxicity (worst per cycle) 
Scheme Topotecan mg m–2 d–1 No. of patients/cycles Nausea grade Vomiting grade 
123 12 3 4  
A 0.45 10/43 15 11 0 7 11 0 1 
B 0.45 2/6 2 4 0 1 4 0 0 
C 0.45 3/18 4 2 0 2 2 0 0 
Ca 0.60 3/18 7 2 1 6 1 0 0 
aPatients who had their topotecan dose reduced to 0.45 mg m–2 d–1 due to earlier toxicity were included in this table. 1128 H Gelderblom et al
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requiring platelet transfusions because of bleeding, the observed
haematological toxicity was, albeit dose-limiting, relatively easy
manageable. Nevertheless dose delays were needed, thereby
limiting the projected dose-intensity in scheme A. Since the
projected dose-intensity could already not be achieved at the first
dose, lower dose was not studied. Also, using the same dose of
topotecan studied in scheme A, in the theoretically less toxic
sequence of cisplatin following topotecan (scheme B) resulted in 2
out of 2 patients experiencing DLT at the first dose level. Therefore,
this schedule was also considered non-feasible. The fact that
topotecan was given on the day of cisplatin administration in both
schedules, with the only difference consisting of an additional
administration of topotecan on the day preceding or following
cisplatin, may have accounted for the lack of the initially expected
sequence-dependent reduction of haematological toxicity in
scheme B. As expected, the drug sequence had no apparent influ-
ence on the severity and frequency of non-haematological side
effects. These side-effects were mostly mild and mainly consisted
of nausea, vomiting, alopecia, headache and neurotoxicity. 
With the addition of CrEL in scheme C, no DLTs were observed
at the first dose level of topotecan at 0.45 mg m–2 and all patients
completed the induction without delays, in contrast to the observa-
tion in scheme A and B. A dose escalation of 33% for topotecan
however again resulted in 2 DLTs in the first 3 patients because of
treatment delay for more than 2 weeks due to persistent haemato-
logical toxicity. The non-haematological side-effects in scheme C
were comparable to those observed for the other 2 schemes. The
number of patients in this study was too small to draw unam-
biguous conclusions on CrELs myeloprotective effect for this
combination. However the fact that (1) no haematological DLTs
were seen in scheme C compared to 4 out of 10 patients at the same
dose level in scheme A, (2) all patients treated on the first dose
level of scheme C completed the cycles without delay, and (3) 11
and 0% of cycles in scheme C resulted in grade 3 or 4 neutropenia
and thrombocytopenia, as compared to respectively 21 and 9% for
scheme A at the same dose level, may all at least suggest a myelo-
protective effect of CrEL. The fact that, nevertheless, a dose escala-
tion in scheme C was impossible is likely related to the fact that
preclinical data indicate a myeloprotective effect of CrEL on
cisplatin toxicity but not on topotecan toxicity, while the adminis-
tered topotecan might have accounted for most of the haematolog-
ical toxicity. A randomised study in a patient population treated
with a cisplatin-based regimen would be required to further eluci-
date CrELs potential myeloprotective effect in patients. 
Pharmacokinetic analysis revealed no interaction between the
compounds in this combination regimen and the apparent clear-
ance of topotecan was independent of dose and schedule. CrEL did
not affect the pharmacokinetics of the cytotoxic agents. 
The scheduled cisplatin dose intensity of the patients
completing all 6 weekly cycles of cisplatin, calculated over a treat-
ment period of 8 weeks was 52.5 mg m–2 week–1. The achieved
median dose intensity of patients completing all 6 weekly induc-
tion cycles was 50.5 mg m–2 week–1 for scheme A; 52.5 mg m–2
week–1 for scheme B; 60 mg m–2 week–1 for scheme C first dose
level; and 39.5 mg m–2 week–1 for scheme C second dose level. In
comparison to the cisplatin dose intensity 17–25 mg m–2 week–1
achieved with the standard 3-weekly cisplatin/oral topotecan
combination regimens (de Jonge et al, 2000; Gelderblom et al,
2000b), the currently achieved dose intensity of cisplatin in this
study is still much higher with all schemes. It is important to note
however, that similar dose-intensity of cisplatin can be also
achieved in combination with agents such as paclitaxel where the
paclitaxel dose-intensity is relatively higher than the currently
feasible topotecan dose intensity. The overall 11% of patients
withdrawn from the induction regimen due to an allergic reaction
to cisplatin is not higher than reported in the literature for highly
cisplatin-pretreated populations (Ciesielski-Carlucci et al, 1997).
Notably, no allergic reactions were observed in the patients treated
with weekly cisplatin preceded by CrEL. 
The response rate of 60% in this heavily pretreated population
with a relatively short cisplatin-free interval is interesting, but not
better compared to weekly cisplatin regimens with agents that can
more easily added than topotecan (van der Burg et al, 1996, 1998). 
In conclusion, this study suggests, but does not prove, some
myeloprotective effect of CrEL on cisplatin-induced toxicity.
However a weekly schedule of cisplatin with oral topotecan seems
less attractive than a weekly combination of cisplatin with either
paclitaxel or etoposide in recurrent ovarian cancer. 
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